EU Clinical Trials EudraCT Number: 2015-002874-19 (MDS CT)
IMO, this is why Janssen is willing to submit Part 1 of Imerge at a major medical conference.
This is Part 2 of the MDS CT:
Part 2: To compare the efficacy, in terms of RBC TI, of imetelstat to placebo in transfusion dependent subjects with low or intermediate-1 risk MDS that is relapsed/refractory to ESA treatment.
Secondary objectives of the trial - To assess the safety of imetelstat in subjects with MDS - To assess the time to RBC TI and duration of RBC TI - To assess the rate of hematologic improvement - To assess the rates of CR or PR - To assess OS - To assess time to progression to AML - To assess the rate and amount of supportive care, including transfusions and myeloid growth factors - To evaluate the pharmacokinetics and immunogenicity of imetelstat in subjects with MDS - To assess the effect of imetelstat treatment on patient reported outcomes (PROs) - To assess the effect of treatment on medical resource utilization
As depressed as anyone to see this stock at $1.99 - but put simply, the pps will not be a factor in whether I sell - I am in to see the results of these trials. I still believe that 'efficacy trends' means efficacy, as already produced in Mayo trials 5 years ago...
Trump never would have gotten elected if the politicians had not failed this country so miserably the last many years. That is how Trump got elected and that is where the real blame lies is on our career politicians that look after themselves and their gold-plated retirements and a gold-plated Healthcare.
Geron is dirt cheap back up your truck and load up.
How can the Fool possibly know a decision is looming by the end of Sept? Fake news? Is this a ploy to let some institutional holders out and leave us bagholders holding the bag of schnitzels? Opinions?
We won't have to wait too much longer to get a better handle on Geron's future. By the end of next September, Johnson & Johnson will make a decision about whether or not to continue developing imetelstat based on results from the recently modified study. If this little biotech's partner gives the thumbs up, you probably won't be able to buy its shares for less than $5 anymore.
3 Top Biotech Stocks Under $5 @themotleyfool #stocks $JNJ, $GSK, $GERN, $AGEN, $INCY, $RIGL
J&J will announce a huge Buyout on GERON sooner than later...
repost from seeking alpha
black, How you doing on holding chippy and co. accountable? I mean really, you been singing that tune for years and I have to ask "how's that work'n for you?"
Racist Steve Bannon has resigned from the Trump team in disgrace. Stock market reacts positively. Now we just need the orange clown to quit and America will be great again.
5 BILLION guys $32 PPS
W/ the 20/80 split on retail sales of IMET, I cannot imagine that JnJ would offer a buy out. They already have the golden goose locked up and will so for years. Opting in will cost 35M, a milestone payment, offering a buy out would cost 1/2 a billion at least. Where's the financial logic? Down the road, if the "billion dollar block buster" forecast by JnJ for IMET holds true, the 20%....200M a year is a large chunk of change and with those kinds of earnings would easily get the stock into the double digits. But buyout?
new patent ( 1 of 177 ) United States Patent 9,732,114 Gryaznov , et al. August 15, 2017 Compounds having anti-adhesive effects on cancer cells
Abstract Compounds of the form O-(x-L)n, where O is an oligonucleoside having at least a plurality of N3'.fwdarw.P5' thiophosphoramidate (NPS) internucleoside linkages, a conjugated lipid moiety L, and at least one G-rich sequence motif as described, are effective to morphologically alter and reduce adhesion of cancer cells.
Inventors: Gryaznov; Sergei M. (San Mateo, CA), Shay; Jerry W. (Dallas, TX), Wright; Woodring (Arlington, TX) Applicant: Name City State Country Type
Gryaznov; Sergei M. Shay; Jerry W. Wright; Woodring San Mateo Dallas Arlington CA TX TX US US US Assignee: GERON CORPORATION (Menlo Park, CA) BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (Austin, TX) Family ID: 1000002778857 Appl. No.: 14/336,443 Filed: July 21, 2014 Prior Publication Data
J&J transferred $20 Billions dollars to the USA....
Study to Evaluate Imetelstat (JNJ-63935937) in Subjects with International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) | Global Trial Finder
The purpose of this study is to evaluate the efficacy and safety of imetelstat in transfusion dependent participants with low or intermediate-1 risk myelodysplastic syndrome (MDS) that is relapsed/refractory to erythropoiesis-stimulating agent (ESA)
Shorts need to buy up 33 million GERN shares and Johnson and Johnson just called GERN'S drug 1 of Johnson and Johnson's top 6 future money makers.
Let's see how hard black works today on a $2. stock.
They're reporting at ASH, we already know what they're going to say. Their drug works better than what's out there. It even works better for people as a front line drug for MDS and MF! And it cures cancer for some with MF. Buying. Buying a lot. I'm going to turn every $1 I put into GERN into $50.